Navigation Links
Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
Date:5/11/2012

lex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a BS degree from State University of New York-Buffalo.

"We congratulate Jeff on his appointment as independent Chairman of the Synthetic Biologics' Board. This important step strengthens Synthetic Biologics' corporate governance practices," stated Jeffrey Riley, Chief Executive Officer, President and Director of the Board at Synthetic Biologics. "Jeff's life science experience will be instrumental in guiding our business and strategic development initiatives."

Upon his appointment Mr. Kraws stated, "I look forward to working closely with Jeff as the Company continues to build its pipeline of synthetic DNA-based therapeutics and innovative medicines for serious illnesses. Transitioning the Chairman role to an independent board member should allow our CEO and his management team to focus on the operations of the Company, with the ultimate objective of increasing value for our shareholders."

About Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be iden
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
2. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
3. Adeona Becomes Synthetic Biologics, Inc.
4. Startling results in synthetic chemistry presented in Nature Chemistry
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
7. Synthetic Biology: Emerging Global Markets
8. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
9. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
10. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
11. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... speciality,pharmaceutical company focused on the discovery and development ... problem of microbial,resistance, announces today the appointment of ... (SAB). Novexel,s SAB is chaired by Dr.,David Shlaes ... who is currently,Adjunct Professor at the Department of ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... company serving the,pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for,fourth-quarter and full-year 2008. ... ), Highlights, ...
... March 25 David Koos, Chairman and CEO of ... BMSN), told the editors of The Wall Street Transcript, ... is an excellent possibility that the company "would have ... alliances and contracts "with companies engaged either in cryogenic ...
Cached Biology Technology:Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview 2
(Date:4/17/2014)... RSV infection , Respiratory syncytial virus (RSV) ... infections, generating life-threating illness in very young and ... limited. RSV enters host cells through the fusion ... bundle. Small interfering peptides that prevent bundle formation ... are highly susceptible to degradation. In this issue ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... apparent paradox exists: Despite choosing a career working with ... from mild disgust to extreme arachnophobia. ... Entomologist features the results of a survey involving ... fear of spiders. Although most entomologists had low scores ...
... producing the building blocks of life, amino acids, in research ... The team from Imperial College London, the University of ... icy comets collide into a planet, amino acids can be ... rocky meteorite crashes into a planet with an icy surface. ...
... has a simple message for fellow hypertension researchers: think ... percent of adults have high blood pressure and 50-75 ... powerful endothelin system, which helps the body eliminate salt, ... research and clinical world focus on suppressing a better-known ...
Cached Biology News:Arachnophobic entomologists: When 2 more legs make a big difference 2Scientists discover cosmic factory for making building blocks of life 2Hypertension researcher encourages colleagues to expand their focus 2Hypertension researcher encourages colleagues to expand their focus 3
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
... The BioPrime Plus Array CGH Genomic Labeling ... enable reproducible labeling of genomic DNA samples ... in both indirect and direct labeling formats, ... Systems provide a flexible solution to your ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Biology Products: